Early sofosbuvir-ledipasvir treatment for acute HCV infection induced severe immune thrombocytopenia – a case report - CIRI - Infection virale, Métabolisme et immunité Access content directly
Journal Articles BMC Infectious Diseases Year : 2018

Early sofosbuvir-ledipasvir treatment for acute HCV infection induced severe immune thrombocytopenia – a case report

Abstract

Background: Hepatitis C virus (HCV) infection is a recognised cause of secondary immune thrombocytopenia (ITP). While its incidence has been largely described during chronic HCV infection, only one case of ITP secondary to acute HCV infection has been reported at this time. Case presentation: We report herein the case of severe ITP secondary to an acute HCV genotype 1a reinfection in a human immunodeficiency virus (HIV)-negative man having sex with men who had been cured several years before of a previous acute genotype 4d HCV infection. After an unsuccessful standard therapy with two courses of intravenous immunoglobulin (at 1 g/kg daily for 2 days) associated with methylprednisolone 1 mg/kg daily, antiviral treatment with sofosbuvir-ledipasvir rapidly achieved virological response and normalised the platelet count. Conclusions: As a direct effect of HCV on megakaryocytes could be the predominant cause of ITP during acute infection, early antiviral treatment may be beneficial in this case.
Fichier principal
Vignette du fichier
12879_2018_Article_3597.pdf (619.72 Ko) Télécharger le fichier
Origin Publisher files allowed on an open archive
Loading...

Dates and versions

inserm-02043152 , version 1 (20-02-2019)

Identifiers

Cite

Vincent Alcazer, Patrick Miailhes, Christophe Ramière, Caroline Charre, Laurent Cotte. Early sofosbuvir-ledipasvir treatment for acute HCV infection induced severe immune thrombocytopenia – a case report. BMC Infectious Diseases, 2018, 18 (1), pp.682. ⟨10.1186/s12879-018-3597-4⟩. ⟨inserm-02043152⟩
108 View
85 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More